Answers are grounded in this paper and cite their sources.
Objectives We aimed to compare early clinical response and low-disease-activity attainment across targeted therapies for radiographic axial spondyloarthritis (r-axSpA), and to determine how well randomised evidence distinguishes active treatments and short-term safety. Methods PubMed, Scopus, Embase, and CENTRAL were searched from inception to 25 August 2026 for phase 2, phase 2/3, and phase 3 randomised trials. The primary outcome was Assessment of SpondyloArthritis international Society 40% response (ASAS40) at 12–16 weeks; Ankylosing Spondylitis Disease Activity Score low disease activity (ASDAS-LDA) was analysed separately as a secondary outcome. Bayesian random-effects network meta-analysis estimated risk ratios (RRs) with 95% credible intervals (CrIs), and confidence was assessed with CINeMA. Results Fifty-one trial families comprising 133 arms and 11556 participants were eligible. The ASAS40 network included 40 studies and 9671 participants. Twenty active regimens had 95% CrIs excluding 1 versus placebo, and 24 of 33 active-versus-placebo comparisons had moderate confidence. At class level, RRs versus placebo were 3.21 (95% CrI 2.44–4.30) for tumour necrosis factor inhibitors, 2.55 (2.10–3.13) for interleukin-17 inhibitors, and 2.34 (1.75–3.18) for Janus kinase inhibitors; the evidence did not establish superiority among active classes. The ASDAS-LDA network included 10 studies and 2425 participants, with CrIs excluding 1 for six active nodes. Clinical harmonisation yielded an estimable 34-node ASAS40 network while retaining all contributing studies and participants. Short-term safety evidence was sparse and did not reliably distinguish active regimens. Conclusions TNF, IL-17, and JAK inhibitors improved early ASAS40 response versus placebo in active r-axSpA. Evidence for ASDAS-LDA was more limited, and the available randomised evidence did not support a robust hierarchy of active treatments or reliable differentiation of short-term safety. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261487257 , identifier CRD420261487257.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: